FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986329161> ?p ?o ?g. }

• W1986329161 endingPage "112" @default.
• W1986329161 startingPage "107" @default.
• W1986329161 abstract "Purpose The role of consolidative radiation therapy (RT) for stage III and IV diffuse large B-cell lymphoma (DLBCL) in the era of rituximab is not well defined. There is evidence that some patients with bulky disease may benefit, but patient selection criteria are not well established. We sought to identify a subset of patients who experienced a high local failure rate after receiving rituximab-based chemotherapy alone and hence may benefit from the addition of consolidative RT. Methods and Materials Two hundred eleven patients with stage III and IV DLBCL treated between August 1999 and January 2012 were reviewed. Of these, 89 had a complete response to systemic therapy including rituximab and received no initial RT. Kaplan-Meier analysis and Cox proportional hazards regression were performed, with local recurrence (LR) as the primary outcome. Results The median follow-up time was 43.9 months. Fifty percent of patients experienced LR at 5 years. In multivariate analysis, tumor ≥5 cm and stage III disease were associated with increased risk of LR. The 5-year LR-free survival was 47.4% for patients with ≥5-cm lesions versus 74.7% for patients with <5-cm lesions (P=.01). In patients with <5-cm tumors, the maximum standardized uptake value (SUVmax) was ≥15 in all patients with LR. The 5-year LR-free survival was 100% in SUV<15 versus 68.8% in SUV≥15 (P=.10). Conclusions Advanced-stage DLBCL patients with stage III disease or with disease ≥5 cm appear to be at an increased risk for LR. Patients with <5-cm disease and SUVmax ≥15 may be at higher risk for LR. These patients may benefit from consolidative RT after chemoimmunotherapy. The role of consolidative radiation therapy (RT) for stage III and IV diffuse large B-cell lymphoma (DLBCL) in the era of rituximab is not well defined. There is evidence that some patients with bulky disease may benefit, but patient selection criteria are not well established. We sought to identify a subset of patients who experienced a high local failure rate after receiving rituximab-based chemotherapy alone and hence may benefit from the addition of consolidative RT. Two hundred eleven patients with stage III and IV DLBCL treated between August 1999 and January 2012 were reviewed. Of these, 89 had a complete response to systemic therapy including rituximab and received no initial RT. Kaplan-Meier analysis and Cox proportional hazards regression were performed, with local recurrence (LR) as the primary outcome. The median follow-up time was 43.9 months. Fifty percent of patients experienced LR at 5 years. In multivariate analysis, tumor ≥5 cm and stage III disease were associated with increased risk of LR. The 5-year LR-free survival was 47.4% for patients with ≥5-cm lesions versus 74.7% for patients with <5-cm lesions (P=.01). In patients with <5-cm tumors, the maximum standardized uptake value (SUVmax) was ≥15 in all patients with LR. The 5-year LR-free survival was 100% in SUV<15 versus 68.8% in SUV≥15 (P=.10). Advanced-stage DLBCL patients with stage III disease or with disease ≥5 cm appear to be at an increased risk for LR. Patients with <5-cm disease and SUVmax ≥15 may be at higher risk for LR. These patients may benefit from consolidative RT after chemoimmunotherapy." @default.
• W1986329161 created "2016-06-24" @default.
• W1986329161 creator A5011635381 @default.
• W1986329161 creator A5013656732 @default.
• W1986329161 creator A5022272969 @default.
• W1986329161 creator A5030186866 @default.
• W1986329161 creator A5076247044 @default.
• W1986329161 creator A5076832426 @default.
• W1986329161 creator A5082059699 @default.
• W1986329161 creator A5082892912 @default.
• W1986329161 date "2015-05-01" @default.
• W1986329161 modified "2023-09-30" @default.
• W1986329161 title "Predictors of Local Recurrence After Rituximab-Based Chemotherapy Alone in Stage III and IV Diffuse Large B-Cell Lymphoma: Guiding Decisions for Consolidative Radiation" @default.
• W1986329161 cites W1911120442 @default.
• W1986329161 cites W1981498525 @default.
• W1986329161 cites W1996879994 @default.
• W1986329161 cites W1998416452 @default.
• W1986329161 cites W2005985010 @default.
• W1986329161 cites W2018071905 @default.
• W1986329161 cites W2019016366 @default.
• W1986329161 cites W2058015212 @default.
• W1986329161 cites W2059457945 @default.
• W1986329161 cites W2065157786 @default.
• W1986329161 cites W2085927974 @default.
• W1986329161 cites W2093967829 @default.
• W1986329161 cites W2102602525 @default.
• W1986329161 cites W2117629472 @default.
• W1986329161 cites W2122356695 @default.
• W1986329161 cites W2122863546 @default.
• W1986329161 cites W2132930280 @default.
• W1986329161 cites W2133201432 @default.
• W1986329161 cites W2144329058 @default.
• W1986329161 cites W2146854986 @default.
• W1986329161 cites W2150587745 @default.
• W1986329161 cites W2160305510 @default.
• W1986329161 cites W2161205944 @default.
• W1986329161 cites W2166337528 @default.
• W1986329161 cites W2327610290 @default.
• W1986329161 cites W2598700764 @default.
• W1986329161 cites W4205736005 @default.
• W1986329161 doi "https://doi.org/10.1016/j.ijrobp.2015.01.025" @default.
• W1986329161 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4394239" @default.
• W1986329161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25863758" @default.
• W1986329161 hasPublicationYear "2015" @default.
• W1986329161 type Work @default.
• W1986329161 sameAs 1986329161 @default.
• W1986329161 citedByCount "21" @default.
• W1986329161 countsByYear W19863291612016 @default.
• W1986329161 countsByYear W19863291612017 @default.
• W1986329161 countsByYear W19863291612018 @default.
• W1986329161 countsByYear W19863291612019 @default.
• W1986329161 countsByYear W19863291612020 @default.
• W1986329161 countsByYear W19863291612021 @default.
• W1986329161 countsByYear W19863291612022 @default.
• W1986329161 countsByYear W19863291612023 @default.
• W1986329161 crossrefType "journal-article" @default.
• W1986329161 hasAuthorship W1986329161A5011635381 @default.
• W1986329161 hasAuthorship W1986329161A5013656732 @default.
• W1986329161 hasAuthorship W1986329161A5022272969 @default.
• W1986329161 hasAuthorship W1986329161A5030186866 @default.
• W1986329161 hasAuthorship W1986329161A5076247044 @default.
• W1986329161 hasAuthorship W1986329161A5076832426 @default.
• W1986329161 hasAuthorship W1986329161A5082059699 @default.
• W1986329161 hasAuthorship W1986329161A5082892912 @default.
• W1986329161 hasBestOaLocation W19863291612 @default.
• W1986329161 hasConcept C126322002 @default.
• W1986329161 hasConcept C143998085 @default.
• W1986329161 hasConcept C146357865 @default.
• W1986329161 hasConcept C151730666 @default.
• W1986329161 hasConcept C2776694085 @default.
• W1986329161 hasConcept C2778559949 @default.
• W1986329161 hasConcept C2779338263 @default.
• W1986329161 hasConcept C2780653079 @default.
• W1986329161 hasConcept C38180746 @default.
• W1986329161 hasConcept C50382708 @default.
• W1986329161 hasConcept C509974204 @default.
• W1986329161 hasConcept C71924100 @default.
• W1986329161 hasConcept C86803240 @default.
• W1986329161 hasConceptScore W1986329161C126322002 @default.
• W1986329161 hasConceptScore W1986329161C143998085 @default.
• W1986329161 hasConceptScore W1986329161C146357865 @default.
• W1986329161 hasConceptScore W1986329161C151730666 @default.
• W1986329161 hasConceptScore W1986329161C2776694085 @default.
• W1986329161 hasConceptScore W1986329161C2778559949 @default.
• W1986329161 hasConceptScore W1986329161C2779338263 @default.
• W1986329161 hasConceptScore W1986329161C2780653079 @default.
• W1986329161 hasConceptScore W1986329161C38180746 @default.
• W1986329161 hasConceptScore W1986329161C50382708 @default.
• W1986329161 hasConceptScore W1986329161C509974204 @default.
• W1986329161 hasConceptScore W1986329161C71924100 @default.
• W1986329161 hasConceptScore W1986329161C86803240 @default.
• W1986329161 hasIssue "1" @default.
• W1986329161 hasLocation W19863291611 @default.
• W1986329161 hasLocation W19863291612 @default.
• W1986329161 hasLocation W19863291613 @default.
• W1986329161 hasLocation W19863291614 @default.
• W1986329161 hasOpenAccess W1986329161 @default.
• W1986329161 hasPrimaryLocation W19863291611 @default.

• next